Meanwhile, the BSE Sensex was down 184.87 points, or 1.99%, to 9396.47.
On BSE, 33,577 shares were traded in the counter. The scrip had an average daily volume of 58,101 lakh shares in the past one quarter.
The stock hit a high of Rs 1087 and a low of Rs 1040 so far during the day. The stock had a 52-week high of Rs 1557.80 on 10 September 2008 and a 52-week low of Rs 890 on 24 January 2008.
The stock had underperformed the market over the past one month till 7 January 2009, rising 3.20% as compared to the Sensex's 6.93% rise. It had also underperformed the market in the past one quarter, falling 22.84% as compared to the Sensex's fall of 18.03%.
India's largest drug maker by market capitalisation has an equity capital of Rs 103.56 crore. Face value per share is Rs 5.
The current price of Rs 1063.50 discounts its Q2 September 2008 annualised EPS of Rs 58.54, by a PE multiple of 18.16.
Sun Pharmaceuticals will replace Satyam Computer Service in the Sensex from 12 January 2009, following a sharp plunge in Satyam's stock price on Wednesday, 7 January 2009, as Satyam chairman Ramalinga Raju resigned after announcing the books of accounts were artificially inflated.
Recently, Sun Pharma had raised its offer by as much as 23% to buy a controlling stake of Israeli drug maker Taro Pharmaceutical Industries. Taro rejected the offer.
Sun Pharmaceuticals, which owns 36% of Taro, on Monday 5 January 2009 disclosed two options to buy the remaining stake in the New York Stock Exchange listed Israeli drug maker Taro Pharmaceutical Industries. The revised offers comes after the Israeli Supreme Court, on 8 December 2008, directed the companies to explore an out-of-court settlement within 30 days.
As per the first option, Sun offered to buy shares at $9.5 each instead of the earlier $7.75 per share. Sun Pharma will have to pay $14 million more than its earlier proposal on this basis. As per the the second option, Sun offered $9 per ordinary share for all shareholders other than Taro Chairman Barrie Levitt and $8.5 per ordinary share for the five million-odd shares held by the promoter group. If this is accepted, Sun's payout will be slightly lower than the first option.
Sun Pharmaceuticals Industries net profit rose 55.6% to Rs 303.14 crore on a 24.6% rise in sales to Rs 929.37 crore in Q2 September 2008 over Q2 September 2007.
Sun Pharma is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several markets across the world.
On BSE, 33,577 shares were traded in the counter. The scrip had an average daily volume of 58,101 lakh shares in the past one quarter.
The stock hit a high of Rs 1087 and a low of Rs 1040 so far during the day. The stock had a 52-week high of Rs 1557.80 on 10 September 2008 and a 52-week low of Rs 890 on 24 January 2008.
The stock had underperformed the market over the past one month till 7 January 2009, rising 3.20% as compared to the Sensex's 6.93% rise. It had also underperformed the market in the past one quarter, falling 22.84% as compared to the Sensex's fall of 18.03%.
India's largest drug maker by market capitalisation has an equity capital of Rs 103.56 crore. Face value per share is Rs 5.
The current price of Rs 1063.50 discounts its Q2 September 2008 annualised EPS of Rs 58.54, by a PE multiple of 18.16.
Sun Pharmaceuticals will replace Satyam Computer Service in the Sensex from 12 January 2009, following a sharp plunge in Satyam's stock price on Wednesday, 7 January 2009, as Satyam chairman Ramalinga Raju resigned after announcing the books of accounts were artificially inflated.
Recently, Sun Pharma had raised its offer by as much as 23% to buy a controlling stake of Israeli drug maker Taro Pharmaceutical Industries. Taro rejected the offer.
Sun Pharmaceuticals, which owns 36% of Taro, on Monday 5 January 2009 disclosed two options to buy the remaining stake in the New York Stock Exchange listed Israeli drug maker Taro Pharmaceutical Industries. The revised offers comes after the Israeli Supreme Court, on 8 December 2008, directed the companies to explore an out-of-court settlement within 30 days.
As per the first option, Sun offered to buy shares at $9.5 each instead of the earlier $7.75 per share. Sun Pharma will have to pay $14 million more than its earlier proposal on this basis. As per the the second option, Sun offered $9 per ordinary share for all shareholders other than Taro Chairman Barrie Levitt and $8.5 per ordinary share for the five million-odd shares held by the promoter group. If this is accepted, Sun's payout will be slightly lower than the first option.
Sun Pharmaceuticals Industries net profit rose 55.6% to Rs 303.14 crore on a 24.6% rise in sales to Rs 929.37 crore in Q2 September 2008 over Q2 September 2007.
Sun Pharma is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several markets across the world.
No comments:
Post a Comment